0001683168-19-001391.txt : 20190507
0001683168-19-001391.hdr.sgml : 20190507
20190507172526
ACCESSION NUMBER: 0001683168-19-001391
CONFORMED SUBMISSION TYPE: D
PUBLIC DOCUMENT COUNT: 1
ITEM INFORMATION: 06b
FILED AS OF DATE: 20190507
DATE AS OF CHANGE: 20190507
EFFECTIVENESS DATE: 20190507
FILER:
COMPANY DATA:
COMPANY CONFORMED NAME: MATEON THERAPEUTICS INC
CENTRAL INDEX KEY: 0000908259
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 133679168
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: D
SEC ACT: 1933 Act
SEC FILE NUMBER: 021-339029
FILM NUMBER: 19804267
BUSINESS ADDRESS:
STREET 1: 701 GATEWAY BLVD.
STREET 2: SUITE 210
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
BUSINESS PHONE: 650-635-7000
MAIL ADDRESS:
STREET 1: 701 GATEWAY BLVD.
STREET 2: SUITE 210
CITY: SOUTH SAN FRANCISCO
STATE: CA
ZIP: 94080
FORMER COMPANY:
FORMER CONFORMED NAME: OXIGENE INC
DATE OF NAME CHANGE: 19930628
D
1
primary_doc.xml
X0708
D
LIVE
0000908259
MATEON THERAPEUTICS INC
701 GATEWAY BLVD.
SUITE 210
SOUTH SAN FRANCISCO
CA
CALIFORNIA
94080
650-635-7000
DELAWARE
OXiGENE, Inc.
OXIGENE INC
Corporation
true
Vuong
Trieu
29397 Agoura Road, Suite 107
Agoura Hills
CA
CALIFORNIA
91301
Executive Officer
Director
William
Schwieterman
701 Gateway Blvd., Suite 210
South San Francisco
CA
CALIFORNIA
94080
Director
Matthew
Loar
701 Gateway Blvd., Suite 210
South San Francisco
CA
CALIFORNIA
94080
Executive Officer
Fatih
Uckun
29397 Agoura Road, Suite 107
Agoura Hills
CA
CALIFORNIA
91301
Executive Officer
Chulho
Park
29397 Agoura Road, Suite 107
Agoura Hills
CA
CALIFORNIA
91301
Executive Officer
Biotechnology
Decline to Disclose
- 06b
false
2019-04-22
false
true
true
Securities issued pursuant to the Agreement and Plan of Merger dated April 17, 2019, among the Issuer and Oncotelic, Inc.
0
John Calcagnini
1406341
Stout Risius Ross Advisors, LLC
127302
10100 SANTA MONICA BLVD., SUITE 1050
LOS ANGELES
CA
CALIFORNIA
90067
CA
CALIFORNIA
NC
NORTH CAROLINA
MN
MINNESOTA
PA
PENNSYLVANIA
false
27000000
27000000
0
Shares of the Issuer's Common Stock and Series A Convertible Preferred Stock issued to stockholders of Oncotelic, Inc. in connection with merger.
false
26
545000
0
0
false
MATEON THERAPEUTICS INC
/s/ Vuong Trieu
Vuong Trieu
CEO
2019-05-07